Evaluation of the Ergogenic Properties of Hesperetin on Exercise-induced Fatigue

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-03

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Twenty young, healthy, physically active men and women (12\~30 years) did a pre-post trial randomized into placebo or HST trials (500 mg/d for two weeks). HST supplementation enhanced endurance judo-specific performance and effectively attenuated exercise-induced fatigue, oxidative stress, inflammatory response, and muscle damage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Astaxanthin Properties on Anti-fatigue

NCT06593535

Healthy Volunteer

COMPLETED NA

Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists

NCT04597983

Power Metabolic Disturbance Change, Body Weight +7 more

COMPLETED NA

Effects of Coenzyme Q10 Supplementation on Oxidative Stress, Antioxidant Capacity, Inflammatory Responses, Fatigue Elimination, and Exercise Performance in Athletes

NCT03321110

Athlete

COMPLETED NA

The Effect of Aspalathus Linearis on Muscle Soreness and Post-exercise Recovery in Young, Physically Inactive Women

NCT06561750

Inflammation Muscle Recovery Muscle Soreness

COMPLETED NA

Effect of Resveratrol Supplementation on Exercise Performance and Recovery

NCT06723119

Effect of Resveratrol on Performance and Recovery

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants in this study will be assigned identification numbers and randomly allocated to either the hesperetin (Hst) trial or the placebo trial. Seven days before the formal exercise performance test, all participants will undergo a maximal oxygen uptake (VO₂max) test using a cycle ergometer. The judo simulation consists of four consecutive 4-minute matches, each separated by a 30-minute rest. Participants will supplement with either placebo or Hst (500 mg/day) for 2 weeks. They are required to fast for 12 hours before the test day. On the experimental day, participants consume a light meal (300 kcal) and intake of either the placebo or Hst capsule, then rest for 1 hour. Afterward, participants perform a 15-minute judo-specific warm-up. All participants are required to complete all three matches. To standardize the judo simulation, opponents will be matched so that weight differences do not exceed 10%. Between the 30-minute rest time, blood samples will be collected and judo-specific physical performance will be evaluated. Immediately following the recovery period of the fourth match, the Special Judo Fitness Test (SJFT) will be evaluated. Judo-specific physical performance assessments will include grip strength, Counter Movement Jump (CMJ), and 10-second Wingate test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Athletes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study recruited 20 healthy male and female participants aged 12 to 30 years with at least 5 years of judo training experience to participate in a single-blind, pre-post test trial. Participants will be randomly assigned to either the hesperetin (Hst) group or the placebo group. All participants must be free from chronic conditions such as heart disease and hypertension, and must not have experienced any serious lower limb musculoskeletal injuries within the past six months. Throughout the study period, participants will be required to maintain their regular daily routines and will be prohibited from consuming any other nutritional supplements or alcohol.

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Containing edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, and palm wax.

Group Type PLACEBO_COMPARATOR

Placebo (Placebo trial)

Intervention Type OTHER

The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)

Hesperetin (Hesperetin trial)

Intervention Type OTHER

The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).

Hesperetin

Each capsule containing 250 mg of Hesperetin

Group Type EXPERIMENTAL

Placebo (Placebo trial)

Intervention Type OTHER

The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)

Hesperetin (Hesperetin trial)

Intervention Type OTHER

The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo (Placebo trial)

The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)

Intervention Type OTHER

Hesperetin (Hesperetin trial)

The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Judo athletes aged 12 to 30 years with at least 5 years of judo training experience.

Exclusion Criteria

* All participants must be free from chronic conditions such as heart disease and hypertension, and must not have experienced any serious lower limb musculoskeletal injuries within the past six months.

Minimum Eligible Age

12 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes